AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23756315 — intervention group
Group type: COMPARATOR
Intervention: Placebo foam
Number of subjects: 100
Study 21175276 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided GIN therapy (GINCS)
Number of subjects: 36
Study 21175276 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled GIN therapy
Number of subjects: 36
Study 19724043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass distribution of oral azithromycin (1 g for adults, 20 mg/kg for children) administered to communities with over 80% coverage for children aged 1 to 9 years.
Number of subjects: 66404
Study 19724043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 1 year) with 18,498 participants.
Number of subjects: 66404
Study 19724043 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated communities (mass azithromycin distribution).
Number of subjects: 66404
Study 15812373 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees data acquisition
Number of subjects: 43
Study 15812373 — intervention group
Group type: COMPARATOR
Intervention: 180 degrees data acquisition
Number of subjects: 43
Study 15812373 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 43
Study 15812373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (180 degrees and 360 degrees)
Number of subjects: 43
Study 12714876 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day lercanidipine (n = 48)
Number of subjects: 92
Study 12714876 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/day amlodipine (n = 44)
Number of subjects: 92
Study 10380951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 6
Study 8891644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast regular saccades
Number of subjects: 0
Study 8891644 — intervention group
Group type: EXPERIMENTAL
Intervention: Express saccades
Number of subjects: 0
Study 8891644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory saccades
Number of subjects: 0
Study 1909286 — intervention group
Group type: EXPERIMENTAL
Intervention: Persumbran (25 mg dipyridamole + 10 mg oxazepam)
Number of subjects: 344
Study 1909286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 6841827 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate food hypersensitivity (food challenges)
Number of subjects: 26
Study 6841827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo challenges)
Number of subjects: 26
Study 31152042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention development process
Number of subjects: 21
Study 31152042 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of intervention's feasibility and long-term sustainability
Number of subjects: 21
Study 31152042 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivers of intervention development
Number of subjects: 21
Study 31152042 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation prioritization
Number of subjects: 21
Study 28660314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 40
Study 28660314 — intervention group
Group type: COMPARATOR
Intervention: Normal gum
Number of subjects: 40
Study 24916684 — intervention group
Group type: EXPERIMENTAL
Intervention: TeenDrivingPlan (TDP)
Number of subjects: 107
Study 24836352 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/lercanidipine combination (20/10 mg)
Number of subjects: 359
Study 24836352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (10 mg)
Number of subjects: 359
Study 24836352 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 359
Study 20854932 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-ARV prophylaxis continued during breastfeeding
Number of subjects: 1140
Study 20854932 — intervention group
Group type: COMPARATOR
Intervention: Short-course ARV prophylaxis stopped at delivery
Number of subjects: 1140
Study 19472862 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing performed by a professional Japanese healer for a 2-month period after a 20-minute group meditation session.
Number of subjects: 17
Study 19472862 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing performed by a professional Japanese healer.
Number of subjects: 17
Study 17589951 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week triple therapy for H pylori eradication
Number of subjects: 45
Study 17589951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study 17589951 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with BD
Number of subjects: 45
Study 16046383 — intervention group
Group type: EXPERIMENTAL
Intervention: ANOVA
Number of subjects: 0
Study 16046383 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression methods
Number of subjects: 0
Study 16046383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative approaches
Number of subjects: 0
Study 12209373 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation (1.6 mg/day) for 12 weeks
Number of subjects: 52
Study 12209373 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 micro g/day) for 6 weeks followed by folic acid and riboflavin (1.6 mg/day) for 12 weeks
Number of subjects: 52
Study 10230249 — intervention group
Group type: EXPERIMENTAL
Intervention: ET1 (soft plastic plate with two parallel protrusions)
Number of subjects: 96
Study 10230249 — intervention group
Group type: EXPERIMENTAL
Intervention: ET2 (characterised by two lines of 7 holes)
Number of subjects: 96
Study 10230249 — intervention group
Group type: COMPARATOR
Intervention: ET1 and ET2
Number of subjects: 96
Study 8691860 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 25 mg/kg body weight
Number of subjects: 36
Study 8691860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 36
Study 1809790 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cyclosporine ophthalmic ointment (dosed once, twice, or thrice daily for 14 days)
Number of subjects: 36
Study 1809790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6135720 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 0.25 mg
Number of subjects: 15
Study 6135720 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 0.5 mg
Number of subjects: 15
Study 6135720 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 1.0 mg
Number of subjects: 15
Study 6135720 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 2.0 mg
Number of subjects: 15
Study 6135720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31256191 — intervention group
Group type: EXPERIMENTAL
Intervention: Active shoulder exercise with a sling suspension system
Number of subjects: 36
Study 31256191 — intervention group
Group type: COMPARATOR
Intervention: Bilateral arm training
Number of subjects: 36
Study 29641366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic sphincterotomy (ES)
Number of subjects: 54
Study 29641366 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic endoscopic sphincterotomy (control group)
Number of subjects: 54
Study 27169627 — intervention group
Group type: EXPERIMENTAL
Intervention: SSG and PRP
Number of subjects: 52
Study 27169627 — intervention group
Group type: COMPARATOR
Intervention: SSG alone
Number of subjects: 52
Study 25203806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 13 to 15 mg/kg/d for 4 weeks
Number of subjects: 112
Study 25203806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 112
Study 25203806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 25203806 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) and Placebo
Number of subjects: 112
Study 22748697 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 140
Study 22748697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 20920220 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention program
Number of subjects: 162
Study 20920220 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study 17624979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion + placebo
Number of subjects: 588
Study 17624979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine + placebo
Number of subjects: 588
Study 17624979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion + nicotine
Number of subjects: 588
Study 17624979 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 588
Study 15591756 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking while performing a simple arithmetic task
Number of subjects: 30
Study 15591756 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking while performing a task of verbal fluency
Number of subjects: 30
Study 15591756 — intervention group
Group type: COMPARATOR
Intervention: Walking alone
Number of subjects: 30
Study 12096010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime plus amikacin
Number of subjects: 969
Study 12096010 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam plus amikacin
Number of subjects: 969
Study 10829372 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary care with telephonic fetal heart rate monitoring
Number of subjects: 81
Study 10829372 — intervention group
Group type: COMPARATOR
Intervention: Conventional care with standard midwifery visits
Number of subjects: 81
Study 10829372 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary care
Number of subjects: 81
Study 8846712 — intervention group
Group type: EXPERIMENTAL
Intervention: ProtoVIEW protocol processing system
Number of subjects: 0
Study 19256150 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g vegetable protein diet
Number of subjects: 5
Study 19256150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable protein diet plus 3 g/day of oral kanamycin
Number of subjects: 5
Study 19256150 — intervention group
Group type: COMPARATOR
Intervention: Single vegetable protein diet
Number of subjects: 5
Study 19256150 — intervention group
Group type: COMPARATOR
Intervention: Vegetable protein diet plus kanamycin
Number of subjects: 5
Study 626697 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 0.5%
Number of subjects: 23
Study 626697 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 1%
Number of subjects: 23
Study 626697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl
Number of subjects: 23
Study 626697 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 31289012 — intervention group
Group type: EXPERIMENTAL
Intervention: Open fetal myelomeningocele repair with incorporation of a skin allograft
Number of subjects: 0
Study 31289012 — intervention group
Group type: COMPARATOR
Intervention: Prenatal repair (as per MOMS trial)
Number of subjects: 0
Study 28927961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF; 20 Hz) DTMS
Number of subjects: 41
Study 28927961 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency (LF; 1 Hz) DTMS
Number of subjects: 41
Study 28927961 — intervention group
Group type: COMPARATOR
Intervention: Sham DTMS
Number of subjects: 41
Study 27643725 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie-Ketogenic (VLCK) diet
Number of subjects: 89
Study 27643725 — intervention group
Group type: COMPARATOR
Intervention: Standard low-calorie diet
Number of subjects: 89
Study 23638978 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU of cholecalciferol for 21 days
Number of subjects: 30
Study 23638978 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 30
Study 23760764 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 80
Study 23760764 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical therapy
Number of subjects: 80
Study 20438741 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF) with cherry Kool Aid solutions sweetened with aspartame at concentrations of 0, 0.01, 0.03, 0.08 and 0.28%
Number of subjects: 34
Study 18434268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam i.v. 8 mg 20 min before incision (Group PRE)
Number of subjects: 60
Study 18434268 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline i.v. 20 mins before incision and lornoxicam i.v. 8 mg after skin closure (Group POST)
Number of subjects: 60
Study 18434268 — intervention group
Group type: COMPARATOR
Intervention: Saline i.v. 5 min before incision and after skin closure (Group C)
Number of subjects: 60
Study 16435640 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal-administered meperidine (0.5 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Number of subjects: 20
Study 16435640 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-administered meperidine (1 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Number of subjects: 20
Study 16435640 — intervention group
Group type: COMPARATOR
Intervention: Submucosal-administered meperidine (0.5 mg/lb)
Number of subjects: 20
Study 16435640 — intervention group
Group type: COMPARATOR
Intervention: Oral-administered meperidine (1 mg/lb)
Number of subjects: 20
Study 12805247 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day vitamin C
Number of subjects: 439
Study 12805247 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day vitamin C
Number of subjects: 439
Study 12805247 — intervention group
Group type: COMPARATOR
Intervention: Dropout group (no supplementation)
Number of subjects: 439
Study 10374220 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg daily
Number of subjects: 56
Study 10374220 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg daily
Number of subjects: 56
Study 10374220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8888662 — intervention group
Group type: EXPERIMENTAL
Intervention: sBNP 10 micrograms/kg
Number of subjects: 27
Study 8888662 — intervention group
Group type: EXPERIMENTAL
Intervention: sBNP 15 micrograms/kg
Number of subjects: 27
Study 1800394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine alone (15-60 mg)
Number of subjects: 33
Study 1800394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine in combination with dilazep (50 mg three times a day)
Number of subjects: 33
Study 1800394 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine alone and in combination with dilazep
Number of subjects: 33
Study 6401172 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG spray 0.8 mg
Number of subjects: 20
Study 6401172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31804131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided interventional interlaminar needling
Number of subjects: 43
Study 29058942 — intervention group
Group type: EXPERIMENTAL
Intervention: To-do list writing for 5 minutes prior to sleep
Number of subjects: 57
Study 29058942 — intervention group
Group type: COMPARATOR
Intervention: Completed activity list writing for 5 minutes prior to sleep
Number of subjects: 57
Study 27901117 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum uric acid (UA) in men
Number of subjects: 3284
Study 27901117 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum uric acid (UA) in women
Number of subjects: 3284
Study 23949064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates (experimental group, n = 18)
Number of subjects: 26
Study 23949064 — intervention group
Group type: COMPARATOR
Intervention: Abdominal breathing and active extremity exercises (control group, n = 8)
Number of subjects: 26
Study 22964150 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNa (either PEG‐IFNa‐2a or PEG‐IFNa‐2b) for 48 weeks
Number of subjects: 96
Study 20351576 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle loading (IML) group
Number of subjects: 18
Study 20351576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 18177774 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year behaviour-change programme delivered by trained facilitators in participants' homes
Number of subjects: 365
Study 18177774 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year behaviour-change programme delivered by telephone
Number of subjects: 365
Study 18177774 — intervention group
Group type: COMPARATOR
Intervention: Brief advice leaflet (control group)
Number of subjects: 365
Study 15811205 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Timolol LA (TLA)
Number of subjects: 12
Study 15811205 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Timolol maleate (TIM)
Number of subjects: 12
Study 15811205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (TLA and TIM)
Number of subjects: 12
Study 12861922 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative efforts between nurse researchers in the United States and Mexico to decrease the risk of HIV infection.
Number of subjects: 0
Study 11222785 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (1 g/kg)
Number of subjects: 33
Study 11222785 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 33
Study 11222785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9429051 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine 70 micrograms.kg‐1 up to 5 mg
Number of subjects: 260
Study 9429051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 9429051 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 260
Study 9429051 — intervention group
Group type: COMPARATOR
Intervention: In-hospital vomiting
Number of subjects: 260
Study 8508192 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5‐mg boron supplement
Number of subjects: 19
Study 8508192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8508192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Boron and Placebo)
Number of subjects: 19
Study 8508192 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron supplementation
Number of subjects: 19
Study 3543767 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg, four times daily for six weeks, initiated during the third trimester)
Number of subjects: 0
Study 3543767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four times daily for six weeks)
Number of subjects: 0
Study 3543767 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg, four times daily for six weeks, initiated during the second trimester)
Number of subjects: 0
Study 3543767 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (150 mg, four times daily for six weeks)
Number of subjects: 0
Study 31711153 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB treatment
Number of subjects: 3979
Study 31160218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day
Number of subjects: 7213
Study 31160218 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/day
Number of subjects: 7213
Study 29382478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing counseling (NC)
Number of subjects: 100
Study 29382478 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study 25157676 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based intervention delivered by newsletters and phone calls over 6 weeks
Number of subjects: 68
Study 25157676 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving information on stress management over 6 weeks
Number of subjects: 68
Study 25157676 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 68
Study 22766391 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39393406
Number of subjects: 39
Study 22766391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 21472661 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-734200 2 mg
Number of subjects: 301
Study 21472661 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-734200 5 mg
Number of subjects: 301
Study 21472661 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-734200 10 mg
Number of subjects: 301
Study 21472661 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-734200 20 mg
Number of subjects: 301
Study 21472661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 18784341 — intervention group
Group type: EXPERIMENTAL
Intervention: gD2 DNA vaccine (100 microg, 300 microg, 1,000 microg, or 3,000 microg)
Number of subjects: 62
Study 18784341 — intervention group
Group type: EXPERIMENTAL
Intervention: gD2 DNA vaccine (3,000 microg)
Number of subjects: 62
Study 18784341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 62
Study 17148534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomisation
Number of subjects: 53
Study 17148534 — intervention group
Group type: COMPARATOR
Intervention: Randomised consent
Number of subjects: 53
Study 14634493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 microg/kg twice daily
Number of subjects: 0
Study 14634493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10871441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 326
Study 10871441 — intervention group
Group type: COMPARATOR
Intervention: Suction curettage abortion
Number of subjects: 326
Study 9335405 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 19
Study 9335405 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 19
Study 9335405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 19
Study 8436250 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 23
Study 8436250 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 23
Study 30402880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of M281 (anti-FcRn antibody) at doses of 15 or 30 mg/kg
Number of subjects: 50
Study 30402880 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50